Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Targeting CD123 to treat myelofibrosis and CMML

Overexpression of CD123 is associated with a number of hematological malignancies, including myelofibrosis and chronic myelomonocytic leukemia (CMML). Data was presented at the 23rd Congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, exploring the impact of novel agent SL-401, which targets CD123, in both of these diseases, as Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, explains in this video. Dr Pemmaraju discusses why such a novel therapy is needed and the positive response rates displayed by patients, as well as the complications often associated with this treatment. Finally, he looks to the future, speaking about his hopes for more positive data, as well as the potential for combining SL-401 with other agents to create new combination therapies.